Publications by authors named "Tomoya Funamoto"

Claim this Profile
A
Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.
Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto

Anticancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report.
Sho Mitsuya, Masahiro Arai, Kiyoe Kanaoka, Tomoya Funamoto, Hiroyuki Tsuji

JTO Clin Res Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Sho Mitsuya, Kenjiro Tsuruoka, Kiyoe Kanaoka, Tomoya Funamoto, Hiroyuki Tsuji

Anticancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
Kei Kunimasa, Toru Oka, Satoshi Hara, Noriyuki Yamada, Satoshi Oizumi, Tomoya Funamoto

Lung Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis